A number of other brokerages have also commented on CRSP. Roth Capital increased their price target on Crispr Therapeutics from $50.00 to $65.00 in a research note on Tuesday, July 30th. William Blair raised Crispr Therapeutics from a market perform rating to an outperform rating in a research note on Tuesday, November 19th. Canaccord Genuity assumed coverage on Crispr Therapeutics in a research note on Friday, July 26th. They set a buy rating and a $72.00 price target for the company. Goldman Sachs Group increased their price target on Crispr Therapeutics from $52.00 to $75.00 and gave the company a neutral rating in a research note on Tuesday, November 19th. Finally, BTIG Research increased their price target on Crispr Therapeutics from $51.00 to $59.00 and gave the company a positive rating in a research note on Tuesday, July 30th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $69.54.
Shares of NASDAQ CRSP traded down $0.67 during mid-day trading on Tuesday, reaching $65.36. The company’s stock had a trading volume of 737,055 shares, compared to its average volume of 1,650,207. The stock has a fifty day moving average of $58.93 and a two-hundred day moving average of $48.44. Crispr Therapeutics has a 52 week low of $22.22 and a 52 week high of $74.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. As a group, equities research analysts predict that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $390,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock worth $3,620,760 over the last quarter. Company insiders own 21.40% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Nikko Asset Management Americas Inc. boosted its position in shares of Crispr Therapeutics by 48.4% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after purchasing an additional 906,006 shares in the last quarter. ARK Investment Management LLC boosted its position in shares of Crispr Therapeutics by 34.7% in the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after purchasing an additional 701,332 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares in the last quarter. Finally, Orbimed Advisors LLC acquired a new stake in shares of Crispr Therapeutics in the 3rd quarter worth $21,167,000. 49.82% of the stock is owned by hedge funds and other institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Dividend Yield
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.